Replies to post #231565 on NorthWest Biotherapeutics Inc (NWBO)

[longfellow95]

Tell me again why anyone thinks this stuff works.

Well, it's on target to beat Optune on survival, datapoint for datapoint, though we obviously don't have arm by arm comparisons yet.

Survival is the most clinically meaningful outcome, by which 'working' should be measured.

[sentiment_stocks]

I'm not sure where she "unwinded" that as Senti asserts but I agree that perhaps not all 25 are psPD.

Initially, LL states this...

25 had stable disease at the two month scan. So you’ve got that first post-radiation scan, and then you had another scan and actually it was stable. So those patients, in retrospect, were probably pseudo progressors, or people that were, you know, were read by radiologists as progression, but were probably pseudo progressors.

And then a few minutes later, she says this...

41:38
So these patients, because they were off trial, we were able to analyze their data early, and this is essentially what that data shows. Of the 25 patients that were pseudo progressors or possibly pseudo progressors, uh ten of them are, err, still alive over three years. They’ve progressed.. uh… they haven’t had any… not even alive… they actually… you know, most of these haven’t even had progression.

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=144937000

When LL starts to break up in her presentation, to me that seems like she's walking it back a bit, knowing that perhaps she shouldn't have claimed they were all psPD. But what do I know... I'm just her unofficial transcriber, lol.

And when you look at the indeterminate chart, you can see a pretty clear break in life expectancy. The first chart dates back to April 2015, so about 8 months after we'd first learned about this group. And you can see where the 11 have begun to separate from the others. And I should note, I don't think psPD patients are typically thought to live just 10 to 20 months.



And in the 2019 chart, the separation between the two groups has become even more apparent.

If Dr, Liau is correct and these are psPD patients, instead of comparing their results to "15-17 months mOS" seen with SOC (as Bosch did here) they should be comparing the results to other psPD patients. Gunjur saw mOS of 27.4 months for his cohort of psPD patients (and DCVax saw only 21.5).

So you see, I'd argue that all of the indeterminate group were NOT pseudo progression patients (no matter what LL says). And coming from that position, and that I can agree that it's likely 11 were psPD, then the percentages, as I see them, were more like this.

3/11 lived to 7 years - so 27% lived 7 years
5/11 lived to 5 years - so 45% lived to 5 years
mOS of that group of 11 - looks to be about 60 vs. Gunjur (whoever that is) saw 27.4.

They called that group of 25 indeterminate for a reason. It was indeterminate. It's likely it comprised both rapid and pseudo and it was you who spent hours arguing with me that at least some of those patients in this group were psPD. This was on the old yahoo board (remember those teeny columns where we could hardly read the responses, lol?!). And I finally came around to admitting that it was likely some of them were - and I thought we'd kind of agreed that it might be these top 11 responders. Anyway, you seem to be backing off from that now... using words like "perhaps"... you're sounding like I did back then, lol.